Nobivac^® Canine Flu H3N8

Features and Benefits

Video: Nobivac Flu - Even Dogs Get The Flu

The First Vaccine to Protect Against Canine Influenza¹

• Approved as an aid in the control of disease associated with canine influenza virus (CIV) infection
• Recommended for use in healthy dogs 6 weeks of age or older
• Contains killed (type A, subtype H3N8) virus combined with an adjuvant to enhance the immune response

Proven to significantly reduce the clinical signs, severity, and spread of canine influenza infection¹

• Reduced the incidence and severity of coughing
• Decreased the overall clinical signs of disease including ocular and nasal discharge, coughing, sneezing, depression, and dyspnea
• Reduced the days and degree of viral shedding
• Demonstrated to protect against the formation and severity of lung lesions

Safety confirmed after a year of clinical use in half a million dogs¹

• Well tolerated on subcutaneous administration
• Proven safe across a multitude of breeds and ages

Easy to administer

• Subcutaneous injection
• Two 1-mL doses given 2 to 4 weeks apart
• Annual revaccination with one dose is recommended

Available in

• 25 x 1 mL dose

Website

www.doginfluenza.com

Reference:

1. Merck Animal Health, data on file.

For further information including complete directions and warnings, please see the PRODUCT LABEL.

Product Label(s) and MSDS